Renal disease. Acute kidney failure
Conditions
Interventions
Intervention 1: Intervention group: The recipient received the oral form (oral or gavage) of melatonin 3 mg tablets manufactured by Razak Company, 3 tablets every 8 hours, starting from the first day
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: age above 18 years Glomerular Filtration Rate more than 30 ml/min received colistin during less 48 hours of admission
Exclusion criteria
Exclusion criteria: Patients undergoing peritoneal or hemodialysis Receiving melatonin 2 weeks before hospitalization Receiving colistin 2 weeks before hospitalization pregnant or breast feeding women Allergy or side effects with melatonin Patients unable to take medications via the gastrointestinal tract since starting colistin(NPO)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daily serum creatinine level. Timepoint: Serum creatinine levels measured daily from the first day to the last day of colistin administration and for at least 5 days. Method of measurement: By taking a sample of the patient's blood and reading serum creatinine using a laboratory device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Review and comparison of acute kidney injury with KDIGO criteria. Timepoint: KDIGO criteria AKI is considered to be an increase of greater than or equal to 0.3 mg/dl in serum creatinine for at least 48 hours, or an increase of 50% or more from baseline for at least 7 days, or a decrease in urine output below 6 cc/kg/hour for 6 hours. Method of measurement: To assess the secondary outcome, which is acute kidney injury based on the KDIGO criteria, serum creatinine in mg/mL and urine volume in mL are used. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGolnaz Afzal
Yazd University of Medical Sciences
Outcome results
None listed